Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00290940 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 2
Development phase
400
Enrollment target
20
Study locations

NCT00290940: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Daiichi Sankyo.

NCT00290940 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Daiichi Sankyo. The registered enrollment target is 400 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00290940, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 2
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG metformin hydrochloride
  • DRUG pioglitazone
  • DRUG CS-917

Study Locations (20)

California

  • - Cudahy
  • - Long Beach
  • - Roseville
  • - Sacramento
  • - Spring Valley
  • - Studio City
  • - Vista
  • - Walnut Creek
  • - West Hills

Florida

  • - Brooksville
  • - Fort Lauderdale
  • - Kissimmee
  • - Miami

Arizona

  • - Mesa
  • - Phoenix
  • - Tempe

Alabama

  • - Birmingham
  • - Northport

Arkansas

  • - Hot Springs

Delaware

  • - Wilmington

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2006-01
Est. Completion 2007-04
Phase Phase 2
Daiichi Sankyo

236 total trials

What the finished NCT00290940 record still lists

NCT00290940 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which metformin hydrochloride is the first listed.

NCT00290940 names 20 study sites across 6 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00290940 about?

NCT00290940 is a clinical study titled "Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917". This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment

What is the current status of trial NCT00290940?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2006-01. Estimated completion is 2007-04.

What conditions does trial NCT00290940 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00290940?

The interventions under investigation include: metformin hydrochloride (DRUG), pioglitazone (DRUG), CS-917 (DRUG).

Who is sponsoring clinical trial NCT00290940?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00290940 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00290940's enrollment target sits among peer trials

400 92nd of 348 higher than 256 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00290940, the US trial registry maintained by the National Library of Medicine. NCT00290940 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.